News tagged with melphalan
Melphalan
Melphalan hydrochloride (trade name Alkeran) is a chemotherapy drug belonging to the class of nitrogen mustard alkylating agents.
An alkylating agent adds an alkyl group (CnH2n+1) to DNA. It attaches the alkyl group to the guanine base of DNA, at the number 7 nitrogen atom of the imidazole ring.
Otherwise known as L-Phenylalanine Mustard, or L-PAM, melphalan is a phenylalanine derivative of mechlorethamine.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Toxicity differences inform decision on conditioning for neuroblastoma transplants
MIAMI—The stem cell transplant regimen that was commonly used in the United States to treat advanced neuroblastoma in children appears to be more toxic than the equally effective regimen employed in Europe and Egypt, according ...
Cancer
Apr 24, 2013 |
not rated yet |
0
In-transit melanoma advance is difficult to predict
(HealthDay)—Progressive disease cannot be reliably predicted by patient, clinical, or procedural factors in patients receiving regional therapy for advanced melanoma of the extremities, according to a study ...
Surgery
Apr 15, 2013 |
not rated yet |
0
Alkylating agent linked to therapy-related leukemia
(HealthDay)—For patients treated for Hodgkin's lymphoma (HL), cumulative doses of alkylating agent (AA) is associated with the risk of therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS), ...
Cancer
Jan 15, 2013 |
5 / 5 (1) |
0
Bortezomib ups response, survival in multiple myeloma
(HealthDay) -- For patients with newly diagnosed multiple myeloma (MM), induction treatment with a combination of bortezomib, doxorubicin, and dexamethasone (PAD) followed by bortezomib maintenance therapy ...
Cancer
Jul 23, 2012 |
not rated yet |
0
Powerful myeloma treatment regimen shows promise for AL amyloidosis
Two studies published today in Blood, the Journal of the American Society of Hematology (ASH), demonstrate preliminary success of an effective multiple myeloma (MM) regimen in patients with AL amyloidosis, a rare and devast ...
Cancer
Feb 13, 2012 |
not rated yet |
0
High-dose melphalan and autologous stem cell transplantation increases survival
A team of researchers led by Boston University School of Medicine (BUSM), has found treatment of selected immunoglobulin light chain (AL) amyloidosis patients with high-dose melphalan and autologous stem cell transplantation ...
Cancer
Oct 26, 2011 |
1 / 5 (1) |
0
|
Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients
Melanoma of the eye (ocular or uveal melanoma) frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients ...
Cancer
Sep 23, 2011 |
4 / 5 (1) |
0
